Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Cedar Crosse Research Center

Neither a doctor nor a teaching hospital

Research payments

$3,191,860

2,846 payments

Through program year 2025, Cedar Crosse Research Center is reported as receiving $3,191,860 in research payments, across 2,846 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $846,877 267
2024 Research $584,281 733
2023 Research $490,525 209
2022 Research $134,789 296
2021 Research $265,251 899
2020 Research $300,101 226
2019 Research $570,036 216

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novo Nordisk AS $1,128,347 2,451 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $495,437 55 payments
  3. AstraZeneca Pharmaceuticals LP $262,247 9 payments
  4. Novartis Pharmaceuticals Corporation $235,252 11 payments
  5. Moderna TX, Inc. $205,235 14 payments
  6. Pfizer Inc. $183,981 49 payments
  7. Eli Lilly and Company $178,304 7 payments
  8. Amgen Inc. $124,189 2 payments
  9. Ipsen Innovation $86,976 74 payments
  10. Biohaven Pharmaceuticals, Inc. $69,420 11 payments
Studies the money was for Research payments · program years 2019–2025
  1. Obesity Long term safety in patients with CV risk $250,445 5 payments
  2. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $247,095 151 payments
  3. A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $205,235 14 payments
  4. Nn9536-4373 $168,422 38 payments
  5. Nn9535-4801 $168,323 987 payments
  6. Nn9536-4375 $166,970 34 payments
  7. A Phase 2 Randomized Doubleblind Placebo Controlled Dose Ranging Dose Finding Parallel Group Study to Assess Efficacy and Safety of Pf07081532 and Open Label Oral Semaglutide in Adults With Type 2 Diabetes Mellitus T2dm Inadequately Controlled on Metformin and Separately Pf07081532 Compared to Matching Placebo in Adults With Obesity But Without T2dm $132,360 31 payments
  8. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $124,678 9 payments
  9. A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients $110,574 2 payments
  10. Nn1250-4252 $102,001 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record